Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:

NCT ID: NCT03844074 Completed - Clinical trials for Age-related Macular Degeneration

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

NCT ID: NCT03835884 Completed - Clinical trials for Diabetic Macular Edema

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Start date: June 24, 2019
Phase: Phase 1
Study type: Interventional

First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)

NCT ID: NCT03834753 Completed - Clinical trials for Age-related Macular Degeneration

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: June 25, 2019
Phase: Phase 3
Study type: Interventional

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

NCT ID: NCT03823300 Completed - Clinical trials for Wet Macular Degeneration

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Start date: March 11, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

NCT ID: NCT03823287 Completed - Clinical trials for Wet Macular Degeneration

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Start date: February 19, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

NCT ID: NCT03803631 Active, not recruiting - AMD Clinical Trials

CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

COCTAEyl
Start date: April 4, 2018
Phase:
Study type: Observational

The main objective of this study is to analyze a new noninvasive imaging examination, OCT angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.

NCT ID: NCT03744806 Completed - Clinical trials for Exudative Age-related Macular Degeneration

Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

Start date: January 2015
Phase:
Study type: Observational

The aim of this study is to evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).

NCT ID: NCT03744767 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

Start date: September 19, 2014
Phase: Phase 2
Study type: Interventional

Prospective, non-comparative, mono-center pilot study. Patients with neovascular age-related macular degeneration (nAMD), responding insufficiently to the maximal standard care with monthly intravitreal anti-VEGF injections are given adjuvant oral mineralocorticoid receptor antagonists for 4 months and observed for any changes in vision or retinal structure during the 4 months of adjuvant treatment, plus 2 additional months without adjuvant treatment.

NCT ID: NCT03699618 Terminated - Clinical trials for Neovascular Age-related Macular Degeneration

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Start date: May 29, 2019
Phase:
Study type: Observational

This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).

NCT ID: NCT03683251 Recruiting - Clinical trials for Neovascular Age-Related Macular Degeneration

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Portal
Start date: September 20, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.